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Leishmania major is the major cause of cutaneous leishmaniosis (CL) outside of the Americas. In the present study
we have cloned six Leishmania genes (H2A, H2B, H3, H4, A2 and HSP70) into the eukaryotic expression vector
pCMVβ-m2a, resulting in pCMV-HISA70m2A, which encodes all six pathoantigenic proteins as a single polyprotein.
This expression plasmid has been evaluated as a novel vaccine candidate in the BALB/c mouse model of CL. The
DNA vaccine shifted the immune response normally induced by L. major infection away from a Th2-specific
pathway to one of basal susceptibility. Immunization with pCMV-HISA70m2A dramatically reduced footpad lesions
and lymph node parasite burdens relative to infected control mice. Complete absence of visceral parasite burden
was observed in all 12 immunized animals but not in any of the 24 control mice. Moreover, vaccinated mice
produced large amounts of IFN-γ, IL-17 and NO at 7 weeks post-infection (pi), and they showed lower arginase
activity at the site of infection, lower IL-4 production and a weaker humoral immune response than infected control
mice. Taken together, these results demonstrate the ability of the HISA70 vaccine to shift the murine immune
response to L. major infection away from an undesirable, Th2-specific pathway to a less susceptible-like pathway
involving Th1 and Th17 cytokine profiles.Introduction
The leishmaniases are a group of diseases caused by in-
fection by several species of the intracellular protozoan
parasites of the genus Leishmania, which are transmitted
by the bite of an infected female phlebotomine sandfly.
Clinical manifestations are divided into three broad cat-
egories, ranging from localized skin ulcers at the site of
the sandfly bite (CL), to disfigurements (mucocutaneous
leishmaniosis, MCL) and a potentially fatal disease of
the viscera (visceral leishmaniosis, VL). These vector-
borne diseases are a global public health problem, affect-
ing an estimated 12 million people around the world. In
fact, 1.5 million new cases of CL and 0.5 million new
cases of VL are reported in humans each year [1].* Correspondence: fjcarrion@vet.ucm.es
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distribution, and reproduction in any mediumDespite their great importance, the leishmaniases are
among the most neglected tropical diseases (NTD) in
the developing world [2]. This is mainly due to their
strong association with poverty: leishmaniases have not
become a very profitable market for the pharmaceutical
sector. However, in recent years, these NTD have come
to affect not only poor countries but also developed
countries as a result of poor sanitary conditions as well
as migration and travel from Leishmania-endemic areas
[3-5]. In addition, climate change and other environ-
mental changes have the potential to expand the geo-
graphical distribution of phlebotomine sandfly species
[6]. Current control programs have focused their atten-
tion on vector and reservoir host control measures or
mass drug distribution. Unfortunately, despite consider-
able progress, no vaccines are available to control any
form of human leishmaniosis [7,8].ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Old World countries, and by L. mexicana and L. amazo-
nensis in Central and South America. In this disease, in-
fection of mammalian host phagocytes results in either
subclinical infection or subacute to chronic disease char-
acterized by lesions and scarring on exposed areas of the
skin. Consequently, although the cutaneous form is not
a lethal disease, people living with CL face significant so-
cial stigma. In addition, failure to treat patients with CL
can give Leishmania parasites time to leave the skin
lesions and invade the bloodstream to spread systemic-
ally in the host [9]. Moreover, depending on the species
of Leishmania involved, cutaneous disease can progress
to destructive MCL. Therefore, local or systemic treat-
ment is important for shortening the disease duration,
managing lesions, especially in the face, improving the
cosmetic aspects of scarring, and avoiding the enormous
social stigma [10,11]. Treatments with antimonial com-
pounds and amphotericin B show variable efficacy, and
they are also toxic and expensive [12]. Clearly, alterna-
tive treatment strategies and new prophylactic vaccines
are needed.
Genetic vaccination is one option to efficiently prime
specific, Th1 mediated host resistance against intracellu-
lar pathogens [13]. The efficacy of DNA vaccines against
experimental leishmaniosis has recently been reviewed
[14]. Leishmania is an intracellular parasite of mamma-
lian phagocytic cells, such as macrophages and dendritic
cells (DC). The outcome of the infection depends on the
type of host immune response elicited. These phagocytic
cells can control Leishmania infection when a Type 1 T
helper (Th1) response is mounted, leading to the induc-
tion of inducible nitric oxide synthase (iNOS) and NO
production, which is the main Leishmania killer mol-
ecule in the murine system [15]. However, Leishmania
can develop several immune evasion tricks to persist in
mammalian phagocytic cells. Cytokines released by Type
2 T helper (Th2) cells increase host cell arginase activity,
producing polyamines that the pathogen uses for sur-
vival [16]. Therefore, the relative strength of the Th1
and Th2 responses remains the governing principle in L.
major immunity. Insights into this theory of Th1/Th2
balance have come from studies in BALB/c mice, which
show T-cell-mediated susceptibility to L. major infection.
In this mouse model, development and progression of the
disease requires sustained production of IL-4 by Th2 cells,
whereas the Th1 response mediated by IL-12, IFN-γ, and
TNF-α is associated with lesion resolution and control of
parasite spread [11,17].
Recent developments are being used to investigate
parasite virulence factors, elucidate immune regulatory
mechanisms and contribute to the development of novel
therapeutics and vaccines for the leishmaniases [18,19].
Recognition of Leishmania antigens by sera frompatients and dogs suffering leishmaniosis is one of the
methods most commonly used for diagnosis and
identification of vaccine candidates against leishmaniosis
[20-25]. Over the last decade, analysis of a Leishmania
cDNA library and its successive fractionation into smal-
ler libraries has resulted in the identification of novel
protective antigens [26,27]. The sequence of events dur-
ing Leishmania infection and the relevance of two dis-
tinct sets of parasite molecules have recently been
reviewed [28]. Inside the susceptible mammalian host,
Leishmania parasites produce surface, secreted and
excreted antigens that help establish infection by pre-
venting premature damage in both parasite and host cell.
Later, intracellular parasite molecules are exposed to the
host immune system. These intracellular antigens are
considered “pathoantigenic” molecules, since they elicit
immunological responses that contribute to disease
pathology [29,30].
These pathoantigens were identified by Western blot
analysis and/or immunoscreening of Leishmania expres-
sion libraries using patient sera [29]. They have attracted
considerable attention because of two remarkable prop-
erties. First, they are recognized specifically by antibodies
that do not cross-react with the host counterparts. This
specificity, which makes pathoantigens a valuable tool in
diagnosis, is due to the fact that their antigenic determi-
nants lie in divergent regions of the sequence, as has
been shown for Leishmania pathoantigens, namely
nucleosome-forming histones (H2A, H2B, H3 and H4)
[21,31], the amastigote-specific A2 protein [32], and the
70-kDa heat shock protein (HSP70) [20,24,25,33].
Second, immunization studies show that some of these
pathoantigens can decrease the pathology-inducing Th2
immune response and increase a therapeutically more ap-
propriate Th1-biased parasite-specific immune response
[34-36].
The main goal of our project is to develop a pathoanti-
genic vaccine able to provide cross-protection against
multiple Leishmania species. In order to design an
improved vaccine against CL, we have cloned the full-
length coding sequences of six Leishmania pathoanti-
genic genes (H2A, H2B, H3, H4, A2 and HSP70) into a
mammalian expression vector that expresses the result-
ing polyprotein, called HISA70, in mammalian cells. The
resulting plasmid, named pCMV-HISA70m2A, was used
to immunize BALB/c mice against virulent L. major
challenge.
Materials and methods
Vaccine preparation
DNA sequences of Leishmania genes were retrieved
from the GeneDB and GenBank databases as follows:
H2A (Lin J21.V3.1160), H2B (Lin.J09.V3.1410), H3
(LinJ10.V3.0920), H4 (Lin J31.V3.3320), A2 (GenBank
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mouse codon-optimized versions of the sequences were
generated using the GeneOptimizer® expert software sys-
tem (Geneart AG) as described elsewhere [37]. The opti-
mized sequences were synthesized chemically by GeneArt
[38] as a single coding region of 4101 bp, named
HISA70m. This sequence encodes a polyprotein of 1367
amino acid residues comprising, from N- to C-terminus,
H2A-H2B-H3-H4-A2-HSP70. To facilitate further plas-
mid construction, XhoI and NotI sites were inserted, re-
spectively, upstream and downstream of the HISA70m
fusion gene, and this expression cassette was cloned into
the eukaryotic expression plasmid pCMVβ-m2A [39]. De-
sign of the plasmid DNA vaccine is shown in Figure 1A.
The expression plasmid pCMV-HISA70m2A and
empty vector pCMVβ-m2A were purified using the
EndoFree plasmid Mega kit (Qiagen, Hilden, Germany)
according to the manufacturer's recommended protocol.
The final pellets of endotoxin-free DNA plasmid were
resuspended in sterile PBS and stored at −20°C until
their use in immunization.
Transfection of plasmid constructs and Western blotting
Expression of HISA70 was detected in mammalian cells
by transiently transfecting pCMV-HISA70m2A into
CHO-K1 cells using Lipofectamine LTX and PLUS Re-
agent (Invitrogen, San Diego, CA, USA) according to the
manufacturer's instructions. Briefly, CHO-K1 cells were
cultured at a density of 4 × 104 cells per well in 24-well
plates in F-12K Nutrient Mixture with Kaighn’s modifi-
cation (Invitrogen) containing 10% FCS and antibiotics;
cells were transfected when they reached 50–80% con-
fluence. Transfected cells were incubated 24 h at 37°C
with 5% CO2. Then the cells were harvested and lysed
by addition of 200 μL per well of Laemmli’s buffer (Bio-
Rad) containing β-mercaptoethanol. Lysates (15 μL)
were resolved by SDS-PAGE. Protein bands were elec-
trophoretically transferred to a PVDF membrane (GE
Healthcare, Madrid, Spain), which was blocked for 1 h
in blocking buffer (10% non-fat milk in PBS-Tween-20).
To detect the antigen blotted on the membrane, a pri-
mary antibody against L. infantum H2A was added at an
appropriate dilution (1:200) and incubated with the
membrane. This antibody was purified from a pool of
anti-histone-positive sera from dogs suffering from VL
[40]. Subsequently the membrane was blotted with a
horseradish peroxidase-conjugated rabbit anti-dog IgG
secondary antibody (1:2000; Cultek, Nordic Immuno-
logical Laboratories, Madrid, Spain).
Experimental animals, parasites and preparation of
soluble antigen
Eight-week-old female BALB/c mice were purchased
from Harlan Interfauna Ibérica (Barcelona, Spain). Theanimals were maintained under standard conditions
approved by the Ethics Committee of Complutense Uni-
versity of Madrid. L. major (clone V1: MHOM/IL/80/
Friedlin) was cultured at 26°C in Schneider’s medium
(Sigma-Aldrich, Madrid, Spain). Soluble Leishmania
antigen (SLA) was prepared from stationary cultures of
L. major promastigotes as previously described [41].
Vaccination and infection of mice
Two groups of mice (n = 6) were immunized subcutane-
ously (s.c.) in the right footpad with 100 μg (in a volume
of 40 μL) of the mammalian expression vector pCMVβ-
m2A alone or with pCMV-HISA70m2A on days −60,
-45 and −30. In parallel, a group of control mice (n = 6)
was inoculated with PBS alone using the same proced-
ure. On day 0 all groups of mice were infected by s.c. in-
jection in the left footpad with 5 × 103 metacyclic L.
major promastigotes in a volume of 30 μL. Metacyclic
forms were previously isolated from stationary cultures
by negative selection using peanut agglutinin (Vector
Laboratories, Barcelona, Spain) [42]. The course of in-
fection was monitored weekly by measuring footpad
swelling with a caliper. Clinical signs of ulceration were
also assessed. Mice were euthanized by cervical disloca-
tion at 7 weeks post-infection (pi), because at this time
the lesions from non-vaccinated groups were larger than
4 mm in diameter or showed signs of ulceration. Drain-
ing lymph nodes (DLN) and spleens were removed from
the euthanized mice. The experiments were carried out
twice in order to evaluate the reproducibility of the
approach.
Generation of bone marrow-derived murine DC
Bone marrow cells were obtained from the femurs and
tibiae of naïve BALB/c mice and cultured in the pres-
ence of 20 ng/mL murine granulocyte macrophage
colony-stimulating factor (GM-CSF; PeproTech, London,
UK), as previously described [43]. On day 7, bone
marrow-derived DC were plated at 1 × 106 cells/mL in 6-
well plates and primed in the presence or absence of SLA
(50 μg/mL). DC were collected at 24 h after pulsing with
SLA and used for in vitro stimulation of T cells as
described below.
In vitro cell culture for determination of cytokine
response and nitric oxide/nitrite production
At sacrifice 7 weeks pi, popliteal-DLN were harvested
and prepared as single-cell suspensions as follows. DLN
cells were washed, resuspended at a final concentration
of 2 × 106/mL in complete medium (DMEM supplemen-
ted with 10% heat-inactivated FCS, 2 mM L-glutamine,
100 U/mL penicillin, and 100 μg/mL streptomycin), and
plated at 1 mL/well in 24-well plates containing bone
marrow-derived DC (5 T cells : 1 DC) that had been left
H2A A2H2B H3 H4
G G G
Xho I: CTCG AG
ATG
TAA 
Not I: G CG G CCG C
G
HSP70
6880 bp
XhoI(641)
Not I(4294)
5´ 3 ´
225
150
102
76
52
38
31
24
17
12
kDa 1   2        3        4  
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B
Figure 1 Construction and testing of the plasmid DNA vaccine. (A) Construction of pCMV-HISA70m2A. At the positions marked “G”, four
tandem repeats of GGC, encoding four Gly residues, were inserted to improve structural flexibility of the HISA70 protein. (B) Analysis of HISA70
expression in CHO-K1 cells after transfection. Lane 1, cells transfected with pCMV-HISA70m2A, 148 kDa; lane 2, cells transfected with empty vector
(pCMVβ-m2A); lane 3, nuclear extracts from L. major promastigotes, 13 kDa; lane 4, untransfected CHO-K1 cells. Protein expression was detected
using specific anti-H2A sera from dogs with leishmaniosis. Proteins were separated on a 10% SDS-PAGE gel. The positions of molecular mass
markers are indicated on the left.
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Cells were co-cultured for 96 h at 37°C and 5% CO2,
and the culture supernatant was collected and stored at
−20°C. Production of antigen-specific IFN-γ (Diaclone,
Besançon, France), IL-4 (eBioscience, Barcelona, Spain)
and IL-17 (R&D Systems, Madrid, Spain) was deter-
mined by ELISA according to the manufacturers’ sug-
gested protocols. Levels of nitrite, which is a byproduct
of nitric oxide production, were measured in culturesupernatants using the Griess assay as previously
described [44]. Briefly, 100 μL of culture supernatants
were mixed with an equal volume of Griess reagent
(Sigma-Aldrich) and incubated at room temperature for
10 min. Absorbance was then measured at 540 nm.
Arginase activity assay
Arginase activity at the site of lesions was determined
ex vivo using 5–10 mL of footpad homogenate as
Domínguez-Bernal et al. Veterinary Research 2012, 43:59 Page 5 of 11
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footpads were rinsed in ethanol and homogenized by
hand in PBS containing 100 U/mL penicillin and 100
μg/mL streptomycin. The homogenate was first centri-
fuged at low speed (50 g) for 5 min to remove large tis-
sue debris, and the supernatant was then centrifuged
again in PBS at high speed (1811 g) for 15 min to pellet
phagocytic cells and amastigotes. Both pellets were incu-
bated for 30 min in 2 mL of lysis buffer (0.1 M Tris–
HCl, 300 μM NaCl, 1 μM PMSF, 1% Triton X-100) and
the lysate was assayed for arginase activity as previously
described [47,48]. One unit of enzyme activity is defined
as the amount of enzyme that catalyzes the formation of
1 mmol of urea/min.
Estimation of parasite burden
Parasite burden in the ipsilateral popliteal-DLN and
spleen was determined at 7 weeks pi by limiting dilution
culture [49]. Briefly, the organs were harvested and a
suspension was prepared by grinding the tissue in 1 mL
of Schneider’s medium (Sigma-Aldrich) containing 20%
FCS in the presence of streptomycin and penicillin.
Four-fold serial dilutions of the homogenized tissue sus-
pensions were plated in a 96-well culture plate and incu-
bated at 26°C for 10 days. Wells were examined for
viable promastigotes. The reciprocal of the highest dilu-
tion factor that was positive for promastigotes was con-
sidered to be the number of Leishmania parasites per
mg of tissue.
Humoral immune response
Leishmania-specific antibodies were quantified by
ELISA. Standard plates were coated overnight at 4°C
with 100 μL of SLA (2 μg/mL) diluted in PBS. After-
wards, wells were washed with PBS supplemented with
0.05% (v/v) Tween-20 and blocked with 2% (w/v) BSA in
PBS. Sera were serially diluted in order to determine the
titer, which was defined as the inverse of the highest
serum dilution factor giving an absorbance > 0.2. Sec-
ondary antibodies were peroxidase-conjugated goat anti-
mouse IgG, IgG1 and IgG2a (1:500, SouthernBiotech,
Madrid, Spain). After washing and addition of peroxid-
ase substrate (ABTS, Roche Diagnostics, Madrid, Spain),
sample absorbance was measured at 405 nm.
Statistical analysis
Since statistical analysis showed that measurements fol-
lowed the standard normal distribution, Student’s t-test
was used to evaluate the significance of differences be-
tween means in the control and experimental groups;
means were the average from two independent experi-
ments. Differences were considered significant when P <
0.05. Statistical analyses were performed using SigmaPlot
software (version 12.2, Systat Software).Results
HISA70 protein can be expressed in CHO-K1 cells
Expression of recombinant proteins by host mammalian
cells transfected with plasmid DNA is an essential re-
quirement for stimulating the host immune system. Ex-
pression of HISA70 in CHO-K1 cells transfected with
pCMV-HISA70m2A was easily detected using an anti-
body against L. infantum H2A (Figure 1B).
Vaccination with pCMV-HISA70m2A confers protection
against L. major infection in BALB/c mice
As expected, immunization of mice with pCMVβ-m2A
alone had no effect on lesion development during the
course of infection. These mice succumbed to progressive
disease. Indeed, the size of footpad swellings (Figure 2A)
and parasite burdens (Figure 2B) in the popliteal-DLN and
spleen of these mice were not significantly different from
those of control mice (PBS) at 7 weeks pi. In contrast,
mice immunized with pCMV-HISA70m2A did not de-
velop lesions at the site of infection or, in some cases, they
developed significantly smaller footpad lesions up to 5
weeks after challenge with L. major, with no signs of ulcer
formation or necrotic tissue. Moreover, the numbers of
parasites in popliteal-DLN were significantly lower in mice
immunized with pCMV-HISA70m2A than in control mice
(PBS or pCMVβ-m2A alone), and immunized mice did
not show the visceralization observed in the control ani-
mals (Figure 2B).
Vaccination with pCMV-HISA70m2A redirects the
L. major-specific Th2 immune response to a less
susceptible-like phenotype
In order to elucidate the type of immune responses eli-
cited by L. major infection, we assessed the production
of IFN-γ, IL-17 and IL-4 in the popliteal-DLN after
stimulation with SLA. As shown in Table 1, DLN cells of
mice vaccinated with pCMV-HISA70m2A produced sig-
nificantly lower levels of specific IL-4 than those of con-
trol mice, but they also produced significantly larger
amounts of IFN-γ and IL-17 at 7 weeks pi. In contrast,
DLN cells of mice immunized with pCMVβ-m2A alone
produced substantial amounts of IL-4, as well as levels
of IFN-γ and IL-17 similar to those of non-vaccinated
mice.
Competition between iNOS and arginase enzymes in
phagocytic cells contribute to the outcome of L. major
infection
Our data showed that arginase activity at the site of infec-
tion was significantly lower in vaccinated mice than in
control animals (Figure 3A). We also measured iNOS
activity indirectly by assaying nitrite production after
stimulating DLN cells with SLA-pulsed DC. We found
significantly higher nitrite levels in cells of mice vaccinated
***
Figure 2 Increased footpad swelling correlated with high parasite burden in control mice at 7 weeks pi. (A) Course of footpad lesion
development in BALB/c mice infected with L. major. (B) Parasite burden in the popliteal-DLN and spleen were determined at 7 weeks pi by
limiting dilution (see Materials and Methods). ND: parasites not detected. Asterisks indicate P < 0.05 with respect to both groups of control mice.
Results are the mean and SD (bars) in groups of mice (n = 6) from two independent experiments.
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mice (Figure 3B). Conversely, no significant difference be-
tween control and pCMVβ-m2A immunized mice was
found at 7 weeks pi.
Characterization of the specific humoral response in
immunized mice
Previous studies in the CL mouse model have reported that
the relative production of immunoglobulin isotypes corre-
lates with the relative strength of induction of Th1- and
Th2-biased immune responses [50,51]. To characterize the
humoral immune response to L. major infection, we mea-
sured levels of IgG1 and IgG2a isotypes in sera of control
and immunized mice at 7 weeks pi (Figure 4A). This ana-
lysis revealed that levels of Leishmania-specific IgG1 anti-
bodies were significantly lower in mice immunized with
pCMV-HISA70m2A than in control mice. Consequently,
the mean Th1/Th2 humoral ratio after infection was signifi-
cantly higher in mice vaccinated with pCMV-HISA70m2A
than in the two control groups (Figure 4B).
Discussion
Attempts to develop immunization protocols to protect
against Leishmania infection have met with mixed success.Table 1 Cytokine production at 7 weeks pi in mice
vaccinated with pCMV-HISA70m2A and in control mice
pg/mL
IFN-γ IL- 17 IL- 4
PBS 600 ± 100 932 ± 50 491 ± 115
pCMVβm2A 650 ± 100 1035 ± 50 380 ± 80
pCMV-HISA70m2A 1102 ± 150 (*) 1300 ± 50 (*) 212 ± 35 (*)
Data are presented as means ± SD and are representative of two independent
experiments with similar results. Asterisks indicate P < 0.05 with respect to
both groups of control mice.A series of studies have documented resistance to infec-
tion after immunization with Leishmania pathoantigens.
Table 2 summarizes data from preclinical studies of poten-
tial vaccines in animal models; these vaccines involve one
or more of the six intracellular pathoantigens used to de-
sign the HISA70 vaccine in the present work (H2A, H2B,
H3, H4, A2 and HSP70).
Immunization studies in mice using various combina-
tions of Leishmania nucleosomal histones, either encoded
in DNA plasmids or pulsed into dendritic cells, have
demonstrated different levels of protection against CL
[40,53] and VL [56]. Unfortunately, only partial reduction
of parasite burden in lymph nodes has been reported
against canine VL [55]. Recent studies have suggested that
the presence or absence of immunodominant epitopes on
histones strongly influences Leishmania parasite persist-
ence, and that Treg cells mediate this effect, suggesting
the complexity of the immunization process [52,54].
The immunogenic properties of Leishmania A2 anti-
gen have been extensively described [69-73]. Several vac-
cine approaches using the A2 antigen have conferred
different levels of protection against murine VL [58-
60,62-64]. Vaccination of dogs using A2 confers partial
protection to canine VL [61], which is significant be-
cause dogs are the main domestic reservoir of viscero-
tropic species of Leishmania. Furthermore, immunizing
mice with a combination of A2 protein and IL-12 or
with an expression vector encoding A2 protected them
against challenge with L. amazonensis, the causative
agent of CL in Latin America [57,58]. Curiously, no
studies have analyzed the ability of A2 antigen vaccines
to protect against L. major infection, which is respon-
sible for CL in humans in the Old World. The most
likely reason is that the L. donovani A2 protein coding
sequence, which is the only one tested so far in vaccines,
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and appears to be absent from L. major and L. tropica
[74].
HSP are abundant intracellular proteins present in all
cells. Since their discovery, HSP have been assigned various
functions, such as folding, assembly, protein transport
and thermotolerance. After exposure to various formsA
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Table 2 Vaccines based on six Leishmania pathoantigens (H2A, H2B, H3, H4, A2 and HSP70)
Antigen Targeted disease Animal model Delivery system Result Reference
H2A/H2B/H3/H4 CL BALB/c DNA vaccine Protection [34]
N-terminal part-H2B CL BALB/c Protein + CpG Protection [52]
H2A/H2B/H3/H4 CL BALB/c Ag-loaded DCs Long-lasting protection [53]
H2A/H3, H2A/H4, H2B/H3, H2B/H4 CL BALB/c DNA vaccine Partial protection [40]
H2A/H2B, H3/H4 CL BALB/c DNA vaccine Partial protection [54]
H1/H2A/H2B/H3/H4 + 5 more Ags VL Dog DNA vaccine Partial protection (DLN) [55]
H2A/H2B/H3/H4 VL BALB/c DNA vaccine No protection [56]
H2A/H2B/H3/H4 VL BALB/c Ag-loaded DCs Partial protection [56]
A2 CL BALB/c Protein + IL-12 Partial protection [57]
A2 CL/VL BALB/c DNA vaccine Partial protection [58]
A2 VL BALB/c DNA vaccine Partial protection (liver) [59]
A2 VL BALB/c Protein + P. acnes Protection (liver) [60]
A2 VL Dog Protein + saponine Partial protection [61]
A2 VL BALB/c A2-Adenovirus Protection [62]
A2 VL BALB/c L. tarentolae Protection [63]
A2 VL BALB/c Live bacteria Partial protection [64]
HSP70 CL BALB/c Primeboost No protection [65]
HSP70 + HSP83 VL BALB/c Protein ± ALD/MPLA Protection (liver) [66]
GP63 + HSP70 VL BALB/c DNA vaccine Protection [67]
GP63 + HSP70 VL BALB/c Protein Protection [68]
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plexes can prime T cell immunity specifically against the
bound peptides, but not against HSP themselves [78].
Indeed, vaccines based on HSP-peptide complexes have
recently been considered for immunotherapy against
cancers and infectious diseases [79].
Among HSP, HSP70 stands out because its complexes
with antigenic peptides can generate a peptide-specific
cellular immune response four orders of magnitude
more efficient than the peptide alone [77]. In the same
way, Leishmania GP63 antigen administered without ad-
juvant elicited partial protection in mice, but when it
was coadministered with HSP70, it conferred protection
against VL [67,68]. Furthermore, a cocktail of HSP70
and HSP83 seems to reduce hepatic parasite burden
against murine VL [66]. In contrast, other authors failed
to demonstrate protection after immunization with
HSP70 alone in a murine CL model [65]. These findings
are consistent with the role of HSP70 as an adjuvant in
antigen presentation, and they suggest that HSP70 must
be bound to antigen to induce an immune response.
This makes sense, because HSP are self-antigens, so they
should not elicit immune responses against themselves
[78,80]. Thus, vaccines based on complexes of HSP and
microbial peptides show promise as safe and effective
therapies against intracellular pathogens.Given the immunogenicity of all six intracellular Leish-
mania pathoantigens, we developed a DNA vaccine that
encodes all six proteins as a single polyprotein (HISA70).
In the present study we found that DNA immunization
of BALB/c mice with pCMV-HISA70m2A induced pro-
tection against L. major infection. Normally, after Leish-
mania invasion in BALB/c mice, infected phagocytic
cells are stimulated by a Th2-type signal, cytokine IL-4,
to express arginase [81]. This inducible enzyme initiates
L-arginine degradation, leading to the synthesis of polya-
mines, which are necessary for Leishmania parasite
growth in infected cells [16]. In the present study,
popliteal-DLN of vaccinated mice showed low levels of
Leishmania-specific IL-4 at 7 weeks pi, which led to sig-
nificantly lower arginase activity at the site of the lesion
in mice vaccinated with pCMV-HISA70m2A than in
control mice. This in turn allowed the development of a
protective anti-Leishmania Th1 response mediated by
NO-dependent IFN-γ production. This was in accord-
ance with previous findings that phagocytic cells can
control Leishmania infection when a Th1 response is
mounted and high levels of NO are produced [15]. NO
is the most important Leishmania killer molecule in the
mouse, and levels of nitrite, a byproduct of NO synthe-
sis, were significantly higher in the vaccinated mouse
than in the control animals.
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pCMV-HISA70m2A expressed significantly higher levels
of specific IL-17 than did the control mice. Our finding
of elevated IL-17 levels in vaccinated mice is consistent
with previous studies in which parasite-specific cellular
responses shifted towards Th1 and Th17 mechanisms of
protective immunity in both VL and CL murine models
[82,83]. IL-17 favors the production of chemokines that
mediate the recruitment of neutrophils as well as Th1
cells [84,85]. Th17 cells secrete IL-17, IL-21, and IL-22,
which exert strong proinflammatory effects that play a
crucial role in fighting Gram-negative bacteria, fungi,
and some protozoa [86]. Indeed, IL-17 mediates control
of parasitemia in mice infected with Trypanosoma con-
golense [87].
We found that the HISA70 vaccine did not enhance
the humoral response in mice. In addition, we assessed
the relative production of IgG2a and IgG1 isotypes, since
these have been widely used as markers, respectively, of
the induction of Th1- and Th2-type immune responses
[51]. Vaccinated mice showed a lower titer of the anti-
SLA IgG1 isotype than did control mice. In contrast,
SLA-specific IgG1 antibodies predominated in control
mice. Thus, vaccination increased the ratio of IgG2a/
IgG1 in protected mice.
In conclusion, vaccination with pCMV-HISA70m2A
successfully promoted Th1- and Th17-type immune
responses, thereby mitigating the Th2 response caused
by L. major infection and creating a resistant-like pheno-
type. As a result, vaccinated mice developed much fewer
and slower-growing lesions than did control mice, and
showed a lower parasite burden at the site of infection,
with no visceralization. These findings suggest the use-
fulness of HISA70 for designing vaccines with improved
protective efficacy against murine CL.
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